WE CLAIM:

1. A method for treating or preventing a condition characterized by airway inflammation in a subject comprising administering one or more histamine H3 receptor antagonists, one or more histamine H4 receptor antagonists and, optionally, one or more histamine H1 receptor antagonists to the subject.

2. The method of claim 1 wherein one or more histamine H3 receptor antagonists are selected from thioperamide, impromidine, burimamide, clobenpropit, impentamine, mifetidine, S-sopromidine, R-sopromidine, clozapine, ciproxifam,



,



,



,



,



,



,



,


,


,


,


,


,


,


,


,


and



3. The method of claim 1 wherein a histamine H3 receptor antagonist and a histamine H4 antagonist is one or more dual H3/H4 antagonists selected from:

5



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



and



4. The method of claim 1 wherein one or more histamine H1 receptor antagonists are selected from astemizole, azatadine, azelastine, acrivastine, brompheniramine, cetirizine, chlorpheniramine, clemastine, cyclizine, carebastine, cyproheptadine, carbinoxamine, desloratadine, doxylamine, dimethindene, ebastine, epinastine, efletirizine, fexofenadine, hydroxyzine, ketotifen, loratadine, levocabastine, mizolastine, mequitazine, mianserin, noberastine, meclizine, norasternizole, picumast, pyrilamine, promethazine, terfenadine, tripelennamine, temelastine, trimeprazine, triprolidine and



5. The method of claim 4 wherein one or more histamine H1 receptor antagonists are selected from loratadine, desloratadine, cetirizine and fexofenadine.

6. The method of claim 1 wherein one or more of the antagonists are combined with a pharmaceutically acceptable carrier in a pharmaceutical composition.

7. The method of claim 6 wherein the pharmaceutical composition is in the form of a pill, capsule or tablet.

8. The method of claim 1 wherein the subject is a human.

9. The method of claim 1 wherein the condition is selected from allergic rhinitis, congestion and pulmonary inflammation.

10. The method of claim 1 wherein one or more of the antagonists are administered to the subject parenterally.

11. The method of claim 1 wherein one or more of the antagonists are administered to the subject non-parenterally.

12. The method of claim 1 wherein the antagonists are administered in a single composition.

13. A combination comprising

(a) one or more histamine H3 receptor antagonist; in association with

(b) one or more histamine H4 receptor antagonist; and, optionally in association with,

(c) one or more histamine H1 receptor antagonist.

14. The combination of claim 13 wherein one or more histamine H3 receptor antagonists are selected from thioperamide, impromidine, burimamide, clobenpropit, impentamine, mifetidine, S-sopromidine, R-sopromidine, clozapine,



,



,



,



,



,



,



,


,


,


,


,


,


,


,


,


and



15. The combination of claim 13 wherein the histamine H3 receptor antagonist and the histamine H4 antagonist is one or more dual H3/H4 antagonists selected from



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



and



16. The combination of claim 13 wherein one or more histamine H1 receptor antagonists are selected from astemizole, azatadine, azelastine, acrivastine, brompheniramine, cetirizine, chlorpheniramine, clemastine, cyclizine, carebastine, cyproheptadine, carbinoxamine, desloratadine, doxylamine, dimethindene, ebastine, epinastine, efletirizine, fexofenadine, hydroxyzine, ketotifen, loratadine, levocabastine, mizolastine, mequitazine, mianserin, noberastine, meclizine, norasternizole, picumast, pyrilamine, promethazine, terfenadine, tripelennamine, temelastine, trimeprazine, triprolidine and



17. The combination of claim 16 wherein one or more histamine H1 receptor antagonists are selected from loratadine, desloratadine, cetirizine and fexofenadine.

18. A pharmaceutical composition comprising a combination of claim 13 and a pharmaceutically acceptable carrier.

19. The composition of claim 18 which is in the form of a pill, capsule or tablet.